| Autor: |
Swindle JD; Farquhar College of Arts and Sciences, Nova Southeastern University, Fort Lauderdale, FL, 33314, USA., Santos KL, Speth RC |
| Jazyk: |
angličtina |
| Zdroj: |
Endocrine [Endocrine] 2013 Oct; Vol. 44 (2), pp. 525-31. Date of Electronic Publication: 2013 Feb 15. |
| DOI: |
10.1007/s12020-013-9898-x |
| Abstrakt: |
The discovery of a novel non-AT1, non-AT2 binding site for angiotensins in the rodent brain and testis that is unmasked by the organomercurial compound para-chloromercuribenzoic acid (PCMB) has catalyzed efforts to purify and characterize this protein. We recently reported that this protein is neurolysin and now report upon the specificity of this binding site for various neuropeptides. Competition binding assays in rat brain and testis used (125)I-Sar(1), Ile(8) angiotensin II (Ang II) as the radioligand in the presence of saturating concentrations of AT1 and AT2 receptor antagonists and 100 μM parachloromercuribenzoate. Primary screening of 36 peptides and other compounds at 10 μM concentration revealed seven peptides that inhibited specific binding >50 %: ghrelin, Tyr(1) S36057 (a melanin-concentrating hormone receptor ligand), orphanin FQ and its congeners (Tyr(1) and Tyr(14)), Dynorphin A (1-8), and Ang (1-9). The selective neurolysin inhibitor Proline-Isoleucine dipeptide was inactive at 1 mM. These results suggest that the ability of PCMB to unmask high affinity binding of Ang II to neurolysin is a pharmacological effect and that neurolysin may significantly affect the activity of the renin-angiotensin system. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full text from SpringerLink